Several clinical cases also report that the combination of gefitinib and letrozole (aromatase inhibitor) showed a synergic anti-tumor effect (24) and the administration of estrogen reduced the effect of gefitinib (25) in patient with lung adenocarcinoma concomitantly expressing ER and EGFR. Here, CYP19A1 is linked to lung adenocarcinoma.